Related Experiment Video
Updated: Nov 1, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with
Jingjuan Feng1,2, Feng Xiang2,3, Jian Cheng2,3
1School of Clinical Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Introduction:
Skin and soft structure infections (SSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) pose serious health risks and cause significant cost burdens, and a conclusive recommendation about antibiotics has not yet been generated. Therefore, we performed this updated network meta-analysis to determine the preferred drug for the treatment of MRSA-caused SSTIs.
Methods:
We searched PubMed, Embase, and Cochrane Library to identify any potentially eligible randomized controlled trials (RCTs) investigating the comparative efficacy and safety of any two of vancomycin, linezolid, tedizolid, and daptomycin in MRSA-caused SSTIs. All statistical analyses were conducted with RevMan, ADDIS, and STATA software.
Results:
Twenty eligible RCTs involving 7804 patients were included for the final analysis. Direct meta-analysis suggested that linezolid was superior to vancomycin in improving clinical (odds ratio [OR], 1.46; 95% confidence interval [CI], 1.07-1.99; P = 0.02) and microbiological (OR, 1.89; 95% CI, 1.24-2.86; P = 0.003) success, which were all confirmed by network meta-analyses. No statistical differences were identified regarding other comparisons. Meanwhile, there were no significant differences between any two antibiotics related to safety. Moreover, ranking probabilities indicated that linezolid had the highest probability of being ranked best in terms of clinical and microbiological success.
Conclusion:
Based on the limited evidence, linezolid may be a preferred antibiotic for the treatment of MRSA-caused SSTIs because it showed superiority in clinical and microbiological success without difference regarding safety.
Insights
Linezolid appears to be a preferred antibiotic for treating methicillin-resistant Staphylococcus aureus (MRSA) skin infections, showing better clinical and microbiological success than vancomycin without safety differences. This finding aids in selecting effective MRSA treatments.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) causes severe skin and soft tissue infections (SSTIs), leading to significant health risks and costs.
- Current antibiotic recommendations for MRSA-SSTIs lack definitive guidance, necessitating comparative efficacy studies.
Purpose of the Study:
- To conduct an updated network meta-analysis comparing vancomycin, linezolid, tedizolid, and daptomycin for MRSA-SSTIs.
- To determine the preferred antibiotic agent for treating MRSA-caused SSTIs based on efficacy and safety.
Main Methods:
- Systematic literature search of PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs).
- Inclusion of RCTs comparing vancomycin, linezolid, tedizolid, and daptomycin for MRSA-SSTIs.
- Statistical analysis using RevMan, ADDIS, and STATA software.
Main Results:
- Twenty RCTs with 7804 patients were analyzed.
- Linezolid demonstrated superior clinical (OR, 1.46; 95% CI, 1.07-1.99) and microbiological (OR, 1.89; 95% CI, 1.24-2.86) success compared to vancomycin.
- No significant differences in safety were found between the antibiotics; linezolid ranked highest for efficacy.
Conclusions:
- Linezolid may be a preferred antibiotic for MRSA-SSTIs due to superior clinical and microbiological outcomes.
- The evidence suggests linezolid offers better efficacy without compromising safety compared to other agents studied.
- Further research may solidify linezolid's role in MRSA-SSTI treatment guidelines.
More Related Videos
Related Concept Videos
Antimicrobial Effectiveness
Combined Effects of Drugs: Synergism
Such synergistic combinations...

